{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=mCRPC+%28Metastatic+Castration-resistant+Prostate+Cancer%29&page=4",
    "query": {
      "condition": "mCRPC (Metastatic Castration-resistant Prostate Cancer)",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 232,
    "total_pages": 24,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=mCRPC+%28Metastatic+Castration-resistant+Prostate+Cancer%29&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=mCRPC+%28Metastatic+Castration-resistant+Prostate+Cancer%29&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T03:59:24.500Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07719361",
      "title": "A Study in Patients With Metastatic Castration-Resistant Prostate Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Castration Resistant Prostate Cancer",
        "mCRPC",
        "mCRPC (Metastatic Castration-resistant Prostate Cancer)",
        "Prostatic Neoplasms",
        "Prostatic Neoplasms, Castration-Resistant",
        "mCRPC or Advanced/Metastatic Solid Tumors",
        "mCRPC, Metastatic Castration Resistant Prostate Cancer",
        "Neoplasms Prostate",
        "Neoplasms of Prostate"
      ],
      "interventions": [
        {
          "name": "FX-111",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Flare Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 60,
      "start_date": "2026-07-01",
      "completion_date": "2029-02-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-07T03:59:24.500Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • Grand Rapids, Michigan + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "East Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07719361"
    },
    {
      "nct_id": "NCT06925737",
      "title": "A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostate Cancer",
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Ifinatamab deruxtecan",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Rescue Medication",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 1440,
      "start_date": "2025-05-13",
      "completion_date": "2031-01-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-07T03:59:24.500Z",
      "location_count": 52,
      "location_summary": "Phoenix, Arizona • Duarte, California • Irvine, California + 40 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06925737"
    },
    {
      "nct_id": "NCT06785636",
      "title": "A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "mCRPC (Metastatic Castration-resistant Prostate Cancer)",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Pocenbrodib",
          "type": "DRUG"
        },
        {
          "name": "Pocenbrodib and Darolutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pathos AI, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 120,
      "start_date": "2025-02-07",
      "completion_date": "2029-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-10-07T03:59:24.500Z",
      "location_count": 19,
      "location_summary": "Fountain Valley, California • Los Alamitos, California • Aurora, Colorado + 16 more",
      "locations": [
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06785636"
    },
    {
      "nct_id": "NCT02826772",
      "title": "Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Castrate Resistant Prostate Cancer (mCRPC)"
      ],
      "interventions": [
        {
          "name": "GT0918",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Suzhou Kintor Pharmaceutical Inc,",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 40,
      "start_date": "2016-02-10",
      "completion_date": "2020-02-15",
      "has_results": false,
      "last_update_posted_date": "2020-03-17",
      "last_synced_at": "2026-10-07T03:59:24.500Z",
      "location_count": 6,
      "location_summary": "Towson, Maryland • Omaha, Nebraska • Las Vegas, Nevada + 3 more",
      "locations": [
        {
          "city": "Towson",
          "state": "Maryland"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "East Setauket",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02826772"
    },
    {
      "nct_id": "NCT03016312",
      "title": "A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Prostatic Neoplasms, Castration-Resistant"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 759,
      "start_date": "2017-01-10",
      "completion_date": "2022-12-20",
      "has_results": true,
      "last_update_posted_date": "2024-08-09",
      "last_synced_at": "2026-10-07T03:59:24.500Z",
      "location_count": 39,
      "location_summary": "Duarte, California • La Jolla, California • Los Angeles, California + 33 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03016312"
    },
    {
      "nct_id": "NCT02987543",
      "title": "Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "olaparib",
          "type": "DRUG"
        },
        {
          "name": "enzalutamide",
          "type": "DRUG"
        },
        {
          "name": "abiraterone acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "MALE",
        "summary": "18 Years to 130 Years · Male only"
      },
      "enrollment_count": 387,
      "start_date": "2017-02-06",
      "completion_date": "2023-02-15",
      "has_results": true,
      "last_update_posted_date": "2023-10-06",
      "last_synced_at": "2026-10-07T03:59:24.500Z",
      "location_count": 35,
      "location_summary": "Anchorage, Alaska • Tucson, Arizona • Duarte, California + 30 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02987543"
    },
    {
      "nct_id": "NCT02130700",
      "title": "Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "VT-464: given orally twice daily in 28-day cycles",
          "type": "DRUG"
        },
        {
          "name": "VT-464: given orally once daily in 28-day cycles",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Innocrin Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 17,
      "start_date": "2014-04",
      "completion_date": "2017-11",
      "has_results": false,
      "last_update_posted_date": "2018-05-07",
      "last_synced_at": "2026-10-07T03:59:24.500Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02130700"
    },
    {
      "nct_id": "NCT05191017",
      "title": "Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "Prostatic Cancer",
        "Cancer of Prostate",
        "Cancer of the Prostate",
        "Prostate Neoplasm",
        "Castrate Resistant Prostate Cancer",
        "Castration Resistant Prostatic Cancer",
        "Castration Resistant Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "NUV-422",
          "type": "DRUG"
        },
        {
          "name": "Enzalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nuvation Bio Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2022-09",
      "completion_date": "2026-07",
      "has_results": false,
      "last_update_posted_date": "2022-08-05",
      "last_synced_at": "2026-10-07T03:59:24.500Z",
      "location_count": 3,
      "location_summary": "Canton, Ohio • Gettysburg, Pennsylvania • Fairfax, Virginia",
      "locations": [
        {
          "city": "Canton",
          "state": "Ohio"
        },
        {
          "city": "Gettysburg",
          "state": "Pennsylvania"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05191017"
    },
    {
      "nct_id": "NCT05682443",
      "title": "ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "ONC-392 low",
          "type": "DRUG"
        },
        {
          "name": "ONC-392 high",
          "type": "DRUG"
        },
        {
          "name": "lutetium Lu 177 vipivotide tetraxetan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OncoC4, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 148,
      "start_date": "2023-12-11",
      "completion_date": "2027-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-10-07T03:59:24.500Z",
      "location_count": 23,
      "location_summary": "Sacramento, California • Aurora, Colorado • Tampa, Florida + 19 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05682443"
    },
    {
      "nct_id": "NCT03098836",
      "title": "Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "ARN-509",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone Acetate",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daniel George, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 93,
      "start_date": "2017-07-10",
      "completion_date": "2024-07-09",
      "has_results": true,
      "last_update_posted_date": "2025-09-12",
      "last_synced_at": "2026-10-07T03:59:24.500Z",
      "location_count": 14,
      "location_summary": "New Orleans, Louisiana • Baltimore, Maryland • Detroit, Michigan + 11 more",
      "locations": [
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Cary",
          "state": "North Carolina"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03098836"
    }
  ]
}